Literature DB >> 24645956

JAK inhibitor in CALR-mutant myelofibrosis.

Francesco Passamonti, Domenica Caramazza, Margherita Maffioli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24645956     DOI： 10.1056/NEJMc1400499

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  23 in total

Review 1.  Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.

Authors:  Brady L Stein; Jason Gotlib; Murat Arcasoy; Marie Huong Nguyen; Neil Shah; Alison Moliterno; Catriona Jamieson; Daniel A Pollyea; Bart Scott; Martha Wadleigh; Ross Levine; Rami Komrokji; Rebecca Klisovic; Krishna Gundabolu; Patricia Kropf; Meir Wetzler; Stephen T Oh; Raul Ribeiro; Rita Paschal; Sanjay Mohan; Nikolai Podoltsev; Josef Prchal; Moshe Talpaz; David Snyder; Srdan Verstovsek; Ruben A Mesa
Journal:  J Natl Compr Canc Netw       Date:  2015-04       Impact factor: 11.908

Review 2.  Efficacy of ruxolitinib for myelofibrosis.

Authors:  Fabio P S Santos; Srdan Verstovsek
Journal:  Expert Opin Pharmacother       Date:  2014-05-24       Impact factor: 3.889

Review 3.  Calreticulin (CALR) mutation in myeloproliferative neoplasms (MPNs).

Authors:  Wenyi Luo; Zhongxin Yu
Journal:  Stem Cell Investig       Date:  2015-08-31

Review 4.  Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions.

Authors:  Jamile M Shammo; Brady L Stein
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

5.  Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin.

Authors:  T Balligand; Y Achouri; C Pecquet; I Chachoua; H Nivarthi; C Marty; W Vainchenker; I Plo; R Kralovics; S N Constantinescu
Journal:  Leukemia       Date:  2016-02-29       Impact factor: 11.528

Review 6.  Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations.

Authors:  Xavier Cahu; Stefan N Constantinescu
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 7.  Unfolding the Role of Calreticulin in Myeloproliferative Neoplasm Pathogenesis.

Authors:  Ross L Levine; Elodie Pronier; Tiffany R Merlinsky
Journal:  Clin Cancer Res       Date:  2019-01-17       Impact factor: 12.531

Review 8.  Novel therapies for myelofibrosis.

Authors:  Brady L Stein; Francisco Cervantes; Francis Giles; Claire N Harrison; Srdan Verstovsek
Journal:  Leuk Lymphoma       Date:  2015-05-18

9.  Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.

Authors:  Shannon Elf; Nouran S Abdelfattah; Edwin Chen; Javier Perales-Patón; Emily A Rosen; Amy Ko; Fabian Peisker; Natalie Florescu; Silvia Giannini; Ofir Wolach; Elizabeth A Morgan; Zuzana Tothova; Julie-Aurore Losman; Rebekka K Schneider; Fatima Al-Shahrour; Ann Mullally
Journal:  Cancer Discov       Date:  2016-03-07       Impact factor: 39.397

Review 10.  Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.

Authors:  Cecilia Arana Yi; Constantine S Tam; Srdan Verstovsek
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.